GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

The tolerability and safety profile for Jemperli combined with carboplatin-paclitaxel was consistent with the known safety profiles of the individual agents. Endometrial cancer originates in the ...

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

FDA approval for Jemperli plus chemotherapy was expanded to include all adult patients with primary advanced or recurrent endometrial cancer in August 2024. More on GSK GSK plc (GSK) 43rd Annual J ...

GSK’s Jemperli (dostarlimab) has been granted expanded approval by the European Commission (EC) to treat a broader range of endometrial cancer patients. The PD-1-blocking antibody has been authorised ...

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

which represent approximately 75% of patients diagnosed with endometrial cancer and who have limited treatment options. The European Commission’s approval to expand the use of Jemperli plus ...